AstraZeneca to buy Actavis lung drugs as Q4 earnings fall short
February 05, 2015 at 02:19 AM EST
LONDON, Feb 5 (Reuters) - AstraZeneca said on Thursday it had agreed to buy Actavis' branded respiratory drug business in the United States and Canada for an initial payment of $600 million as it seeks external deals to ensure growth.